Epoprostenol inhalation - Aerogen
Alternative Names: VentaProstLatest Information Update: 31 Oct 2021
At a glance
- Originator Aerogen
- Developer Aerogen; Ohio State University
- Class 2 ring heterocyclic compounds; Antihypertensives; Prostaglandins; Small molecules; Vasodilators
- Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II SARS-CoV-2 acute respiratory disease
- No development reported Pulmonary hypertension
Most Recent Events
- 29 Jun 2021 Aerogen Pharma completes a phase II VPCOVID trial in SARS-COV-2 acute respiratory disease in USA (Inhalation) (NCT04452669)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Pulmonary-hypertension(In the elderly, In adults) in USA (Inhalation, Liquid)
- 30 Jun 2020 Aerogen Pharma in collaboration with Ohio State University plans to initiate a phase II trial for Adult respiratory distress syndrome in USA, in July 2020 (NCT04452669)